Vaccines

Sep 14, 2017
By Pharmaceutical Technology Editors
Shingrix represents a new, possibly better alternative to existing treatments.
Aug 28, 2017
By Pharmaceutical Technology Editors
FDA halts unproved stem-cell cancer treatments administered to California patients, which was derived from a commercially unavailable military-grade vaccine.
Aug 28, 2017
By Pharmaceutical Technology Editors
The acquisition of Protein Sciences, a vaccines biotechnology company, strengthens Sanofi’s influenza vaccines portfolio.
Aug 09, 2017
By Pharmaceutical Technology Editors
Through its life-sciences business, MilliporeSigma, Merck KGaA will collaborate with Baylor College of Medicine to advance vaccine development for neglected and emerging diseases.
Aug 09, 2017
By Pharmaceutical Technology Editors
FDA requests more detailed information on a post-marketing study for Dynavax’s hep-B vaccine, which will require an extended review time past its August 2017 PDUFA date.
Jul 31, 2017
By Pharmaceutical Technology Editors
Partnership aims to develop new vaccine regimens against hep B and HIV by combining respective proprietary vaccine technologies.
Jul 24, 2017
By Pharmaceutical Technology Editors
GE Healthcare partners with Oritain for an independent test that can confirm the country of origin of fetal bovine serum (FBS), a component of biopharmaceutical production.
Jul 17, 2017
By Pharmaceutical Technology Editors
GSK plans to deliver up to 40 million doses of its quadrivalent flu vaccine for the 2017–2018 season.
Jul 11, 2017
By Pharmaceutical Technology Editors
The acquisition will add recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio
Jun 28, 2017
By Pharmaceutical Technology Editors
Two recently-signed agreements will transfer Takeda’s measles and acellular pertussis vaccine technologies to India-based multinational company Biological E. Limited to develop low-cost combination vaccines including diphtheria, tetanus and acellular pertussis (DTaP), and measles-rubella (MR) vaccines.
native1_300x100
lorem ipsum